Virginia Powers, PhD

Articles

Ramucirumab Benefit for US Patients With Gastric Cancer Mirrors Global Results

June 27th 2014

A geographic analysis of clinical trial results supporting the use of ramucirumab in advanced gastric cancer demonstrated that patients in the United States and other Western nations experienced similar survival gains and adverse events as did their counterparts in two other regions of the world.

Regorafenib Offers Effective Option for Asian Patients With mCRC

June 27th 2014

Treatment with regorafenib significantly improved OS and PFS in an Asian population of patients with previously treated mCRC.

Ruxolitinib Combo Improves Outcomes in Metastatic Pancreatic Cancer

June 26th 2014

Adding ruxolitinib to capecitabine as a second-line treatment for patients with metastatic pancreatic cancer significantly improved survival for a subgroup with a high degree of local and systemic inflammation compared with capecitabine plus placebo.

Adding Cetuximab to Chemoradiation in Non-operable Esophageal Cancer Does Not Improve Survival

June 26th 2014

Adding cetuximab to concurrent chemoradiotherapy did not improve overall survival in patients with adenocarcinoma or squamous cell carcinoma of the esophagus

Prognostic Scale Developed for Overall Survival in Locally Advanced Pancreatic Cancer

June 26th 2014

Four independent prognostic factors for improved overall survival in patients with locally advanced pancreatic cancer emerged from an analysis of the LAP 07 phase III trial.